Domain To Bring First Wholly Owned GCPR Asset Into Clinic

After Building Reputation Through Partnerships

19 Oct 2022

• By Ayisha Sharma

The French firm is going it alone for the first time with a planned Phase I trial for its lead EP4 receptor antagonist in cancer after years of sharing its technology and GCPR expertise with big pharma.

Birds flying in a group with one lone bird flying separately — Domain Is Forging An Independent Path For The First Time • Source: Shutterstock

Domain Therapeutics S.A. is advancing its first wholly owned drug candidate, DT-9081, into in-human studies later this year, drawing upon its G protein-coupled receptors (GPCR) expertise built up through collaborations.

The firm’s lead program has cleared clinical trial applications at agencies in France and Belgium with a Phase Ia study...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

17 Jun 2025

• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

17 Jun 2025

• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

16 Jun 2025

• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.